<DOC>
	<DOCNO>NCT00216814</DOCNO>
	<brief_summary>To determine association basic fibroblast growth factor , vascular endothelial growth factor , interleukin level patient response BCG treatment ( standard treatment ) urine patient superficial TCC . To determine level angiogenic factor predict response BCG , disease recurrence , progression risk factor .</brief_summary>
	<brief_title>Antiangiogenic Effects BCG Urinary Concentration Angiogenic Factors</brief_title>
	<detailed_description>200 patient candidate intravesical BCG therapy 20 control patient history malignancy enrol . The study group wol ; ; ask provide urine sample prior receive first BCG treatment ( week # 1 ) prior receive last ( week # 6 ) BCG treatment . The control patient provide one urine sample . Samples analyse enzyme-linked immunosorbant assay ( ELISA ) . clinical data review tumor stage grade prior BCG , timme recurrence , tumor stage grade recurrence , time disease progression death , cause death total follow-up time .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>200 study group 1 . Must candidate BCG therapy . 20 control group 1 . No history malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>antiangiogenic effect bcg treatment prognosis</keyword>
</DOC>